Vinpocetine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vinpocetine" in English language version.

refsWebsite

Global rank English rank

19nih.gov

4^th place

12doi.org

2^nd place

3fda.gov

447^th place

338^th place

1newsweek.com

269^th place

201^st place

1nutraingredients-usa.com

low place

1nutraceuticalsworld.com

low place

1pressreader.com

953^rd place

647^th place

1ftc.gov

3,796^th place

2,268^th place

1acs.org

1,248^th place

1,104^th place

1worldcat.org

5^th place

1harvard.edu

18^th place

17^th place

1semanticscholar.org

11^th place

8^th place

1tampabay.com

829^th place

485^th place

1sciencebasedmedicine.org

5,063^rd place

3,360^th place

1ocregister.com

1,086^th place

618^th place

1natlawreview.com

9,177^th place

5,024^th place

1naturalproductsinsider.com

low place

acs.org

cen.acs.org

Erickson BE (October 31, 2016). "Vinpocetine: drug or dietary supplement?". Chemical & Engineering News. 94 (43): 16–17. ISSN 0009-2347. Retrieved December 28, 2018.

doi.org

Zhang YS, Li JD, Yan C (January 2018). "An update on vinpocetine: New discoveries and clinical implications". European Journal of Pharmacology. 819: 30–34. doi:10.1016/j.ejphar.2017.11.041. PMC 5766389. PMID 29183836.
Avula B, Chittiboyina AG, Sagi S, Wang YH, Wang M, Khan IA, et al. (March 2016). "Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States". Drug Testing and Analysis. 8 (3–4): 334–343. doi:10.1002/dta.1853. PMID 26426301.
Cohen PA (October 2015). "Vinpocetine: An Unapproved Drug Sold as a Dietary Supplement". Mayo Clinic Proceedings. 90 (10): 1455. doi:10.1016/j.mayocp.2015.07.008. PMID 26434971.
Szatmari SZ, Whitehouse PJ (2003). "Vinpocetine for cognitive impairment and dementia". The Cochrane Database of Systematic Reviews. 2003 (1): CD003119. doi:10.1002/14651858.CD003119. PMC 8406981. PMID 12535455.
Bereczki D, Fekete I (January 2008). "Vinpocetine for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 2008 (1): CD000480. doi:10.1002/14651858.CD000480.pub2. PMC 7034523. PMID 18253980.
McDaniel MA, Maier SF, Einstein GO (2003). ""Brain-specific" nutrients: a memory cure?". Nutrition. 19 (11–12): 957–975. doi:10.1016/S0899-9007(03)00024-8. PMID 14624946.
Gutiérrez-Farfán I, Reyes-Legorreta C, Solís-Olguín M, Alatorre-Miguel E, Verduzco-Mendoza A, Durand-Rivera A (April 2021). "Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study". Journal of Pharmacological Sciences. 145 (4): 313–318. doi:10.1016/j.jphs.2021.01.010. PMID 33712282.
Hagiwara M, Endo T, Hidaka H (February 1984). "Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle". Biochemical Pharmacology. 33 (3): 453–457. doi:10.1016/0006-2952(84)90240-5. PMID 6322804.
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, et al. (May 2010). "Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism". Proceedings of the National Academy of Sciences of the United States of America. 107 (21): 9795–9800. doi:10.1073/pnas.0914414107. PMC 2906898. PMID 20448200.
Medina AE (June 2010). "Vinpocetine as a potent antiinflammatory agent". Proceedings of the National Academy of Sciences of the United States of America. 107 (22): 9921–9922. Bibcode:2010PNAS..107.9921M. doi:10.1073/pnas.1005138107. PMC 2890434. PMID 20495091.
Trejo F, Nekrassov V, Sitges M (August 2001). "Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings". Brain Research. 909 (1–2): 59–67. doi:10.1016/S0006-8993(01)02621-X. PMID 11478921. S2CID 38990597.
French JM, King MD, McDougal OM (May 2016). "Quantitative Determination of Vinpocetine in Dietary Supplements". Natural Product Communications. 11 (5): 607–609. doi:10.1177/1934578X1601100512. PMC 5345962. PMID 27319129.

fda.gov

Office of the Commissioner (3 June 2019). "Statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine". FDA. Retrieved 5 June 2019.
"Vinpocetine in Dietary Supplements". FDA. February 22, 2023. Retrieved June 9, 2023.
Office of the Commissioner (2019-06-03). "Statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine". FDA. Retrieved 2019-06-04.

ftc.gov

"Supplement Marketers Will Relinquish $1.4 Million to Settle FTC Deceptive Advertising Charges". Federal Trade Commission. U.S. Federal Trade Commission. July 8, 2015. Retrieved January 1, 2019.

harvard.edu

ui.adsabs.harvard.edu

Medina AE (June 2010). "Vinpocetine as a potent antiinflammatory agent". Proceedings of the National Academy of Sciences of the United States of America. 107 (22): 9921–9922. Bibcode:2010PNAS..107.9921M. doi:10.1073/pnas.1005138107. PMC 2890434. PMID 20495091.

natlawreview.com

"Procera AVH Marketers Can Forget About Claiming to Reverse Memory Loss". National Law Review. July 30, 2015. Retrieved 1 January 2019.

naturalproductsinsider.com

Myers S (July 8, 2015). "Memory Supplement Marketers Settle FTC Case for $150M". Natural Products Insider. Retrieved 1 January 2019.

newsweek.com

Schmitt R (January 12, 2017). "Marketers exploit the aged with unproven brain-health claims". Newsweek. Retrieved January 18, 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Zhang YS, Li JD, Yan C (January 2018). "An update on vinpocetine: New discoveries and clinical implications". European Journal of Pharmacology. 819: 30–34. doi:10.1016/j.ejphar.2017.11.041. PMC 5766389. PMID 29183836.
Avula B, Chittiboyina AG, Sagi S, Wang YH, Wang M, Khan IA, et al. (March 2016). "Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States". Drug Testing and Analysis. 8 (3–4): 334–343. doi:10.1002/dta.1853. PMID 26426301.
Cohen PA (October 2015). "Vinpocetine: An Unapproved Drug Sold as a Dietary Supplement". Mayo Clinic Proceedings. 90 (10): 1455. doi:10.1016/j.mayocp.2015.07.008. PMID 26434971.
Szatmari SZ, Whitehouse PJ (2003). "Vinpocetine for cognitive impairment and dementia". The Cochrane Database of Systematic Reviews. 2003 (1): CD003119. doi:10.1002/14651858.CD003119. PMC 8406981. PMID 12535455.
Bereczki D, Fekete I (January 2008). "Vinpocetine for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 2008 (1): CD000480. doi:10.1002/14651858.CD000480.pub2. PMC 7034523. PMID 18253980.
McDaniel MA, Maier SF, Einstein GO (2003). ""Brain-specific" nutrients: a memory cure?". Nutrition. 19 (11–12): 957–975. doi:10.1016/S0899-9007(03)00024-8. PMID 14624946.
Gutiérrez-Farfán I, Reyes-Legorreta C, Solís-Olguín M, Alatorre-Miguel E, Verduzco-Mendoza A, Durand-Rivera A (April 2021). "Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study". Journal of Pharmacological Sciences. 145 (4): 313–318. doi:10.1016/j.jphs.2021.01.010. PMID 33712282.
Hagiwara M, Endo T, Hidaka H (February 1984). "Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle". Biochemical Pharmacology. 33 (3): 453–457. doi:10.1016/0006-2952(84)90240-5. PMID 6322804.
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, et al. (May 2010). "Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism". Proceedings of the National Academy of Sciences of the United States of America. 107 (21): 9795–9800. doi:10.1073/pnas.0914414107. PMC 2906898. PMID 20448200.
Medina AE (June 2010). "Vinpocetine as a potent antiinflammatory agent". Proceedings of the National Academy of Sciences of the United States of America. 107 (22): 9921–9922. Bibcode:2010PNAS..107.9921M. doi:10.1073/pnas.1005138107. PMC 2890434. PMID 20495091.
Trejo F, Nekrassov V, Sitges M (August 2001). "Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings". Brain Research. 909 (1–2): 59–67. doi:10.1016/S0006-8993(01)02621-X. PMID 11478921. S2CID 38990597.
French JM, King MD, McDougal OM (May 2016). "Quantitative Determination of Vinpocetine in Dietary Supplements". Natural Product Communications. 11 (5): 607–609. doi:10.1177/1934578X1601100512. PMC 5345962. PMID 27319129.

ncbi.nlm.nih.gov

Zhang YS, Li JD, Yan C (January 2018). "An update on vinpocetine: New discoveries and clinical implications". European Journal of Pharmacology. 819: 30–34. doi:10.1016/j.ejphar.2017.11.041. PMC 5766389. PMID 29183836.
Szatmari SZ, Whitehouse PJ (2003). "Vinpocetine for cognitive impairment and dementia". The Cochrane Database of Systematic Reviews. 2003 (1): CD003119. doi:10.1002/14651858.CD003119. PMC 8406981. PMID 12535455.
Bereczki D, Fekete I (January 2008). "Vinpocetine for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 2008 (1): CD000480. doi:10.1002/14651858.CD000480.pub2. PMC 7034523. PMID 18253980.
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, et al. (May 2010). "Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism". Proceedings of the National Academy of Sciences of the United States of America. 107 (21): 9795–9800. doi:10.1073/pnas.0914414107. PMC 2906898. PMID 20448200.
Medina AE (June 2010). "Vinpocetine as a potent antiinflammatory agent". Proceedings of the National Academy of Sciences of the United States of America. 107 (22): 9921–9922. Bibcode:2010PNAS..107.9921M. doi:10.1073/pnas.1005138107. PMC 2890434. PMID 20495091.
French JM, King MD, McDougal OM (May 2016). "Quantitative Determination of Vinpocetine in Dietary Supplements". Natural Product Communications. 11 (5): 607–609. doi:10.1177/1934578X1601100512. PMC 5345962. PMID 27319129.

ntp.niehs.nih.gov

National Toxicology Program (September 2013). "Chemical Information Review Document for Vinpocetine (CAS No. 42971-09-5)" (PDF). U.S. Department of Health and Human Services. Retrieved December 28, 2018.

nutraceuticalsworld.com

"FDA Concludes Vinpocetine Ineligible as a Dietary Ingredient". Nutraceuticals World. Rodman Media. September 20, 2016. Retrieved January 18, 2017.

nutraingredients-usa.com

Hank S (7 September 2016). "FDA rules vinpocetine not a legal dietary ingredient despite successful NDI filings". NutraIngredients. William Reed Business Media, England. Retrieved September 8, 2016.

ocregister.com

Almada B (July 6, 2015). "False claims for brain supplement draw $152 million penalty from FTC". Orange County Register. Retrieved January 1, 2019.

pressreader.com

Schmitt R (February 3, 2017). "Dubious doses". Newsweek. Retrieved September 24, 2017.

sciencebasedmedicine.org

Hall H (September 18, 2012). "Procera AVH: A Pill to Restore Memory". Science Based Medicine. Retrieved January 1, 2019.

semanticscholar.org

api.semanticscholar.org

Trejo F, Nekrassov V, Sitges M (August 2001). "Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings". Brain Research. 909 (1–2): 59–67. doi:10.1016/S0006-8993(01)02621-X. PMID 11478921. S2CID 38990597.

tampabay.com

McGrory K (July 9, 2015). "Tampa diet supplement firm pays $1.4 million settlement over 'brain power' pill claims". Tampa Bay Times. Retrieved January 1, 2019.

worldcat.org

search.worldcat.org

Erickson BE (October 31, 2016). "Vinpocetine: drug or dietary supplement?". Chemical & Engineering News. 94 (43): 16–17. ISSN 0009-2347. Retrieved December 28, 2018.